Oral Peptide vs Dual Incretin — Metabolic Deal Terms Comparison
Market Analysis
In metabolic, Oral Peptide and Dual Incretin represent two of the most actively transacted modalities. At Phase 2, Oral Peptide deals carry a median total deal value of $6.7B with $1.4B upfront, compared to $5.9B total value and $1.2B upfront for Dual Incretin. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Oral Peptide development milestones average $954M versus $839M for Dual Incretin. Commercial milestones are $3.2B for Oral Peptide and $2.8B for Dual Incretin. Royalty rates range from 18.1%-30% for Oral Peptide and 17.4%-30% for Dual Incretin.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Oral Peptide and Dual Incretin deal terms compare in metabolic?
Which modality commands higher royalty rates: Oral Peptide or Dual Incretin?
How do milestone structures differ between Oral Peptide and Dual Incretin?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.